R.E.A.C.H-ing for Higher Standards in Global Chemical Management
Article Mar 29, 2017 | Original Story By Helen Gillespie for Technology Networks
Upcoming Helsinki Chemicals Forum (HCF) to focus on REACH regulation, chemical safety and impact on and integration with country-specific regulations.
The challenges of defining and managing chemicals in today’s interconnected global environment are more difficult than ever before. Despite the publication of the TSCA (Toxic Chemical Substances Act) regulation in the United States, the recent political changes are casting doubt on how or what will be changed, despite the pressing need for change.
Regardless of what is happening in the US concerning chemical regulations, the European Commission (EC) has been intent on removing and reducing toxic substances from industrial products that are manufactured in and imported into Europe. To this end, the European Chemicals Agency (ECHA) was formed to draft and manage a new regulation for monitoring this process: REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals).
REACH establishes procedures for collecting and assessing information on chemical substance hazards and risks.
It requires companies to register the substances they manufacture in, or import into, Europe above one tonne a year. The goal is to gather information on chemicals within the European Union (EU) in order to manage chemical risks in a meaningful way, as well as to promote the gradual substitution of the most toxic substances.
What makes the regulation different from most is that REACH is not a voluntary standard. It places the burden of proof on industry to demonstrate that a substance is safe.
Rather than acting as a watchdog and demonstrating that a substance is unsafe, ECHA is evaluating the chemical data that the manufacturer provides. As a result, there is now a much better understanding of chemical substances, with the most dangerous substances being replaced with safer alternatives.
One of the greatest hurdles REACH is addressing is the cost to comply. It is not only expensive to reconfigure a product or substitute a less toxic substance, it is also expensive and time-consuming to provide the information to REACH. Historically, businesses have been more focused on profits than product safety so any additional cost that impacts their bottom line is met with resistance. However there is no turning back from the greater knowledge that now exists concerning the impact of toxic substances.
The REACH regulation and the challenges and issues surrounding chemicals management will be addressed at the upcoming Helsinki Chemicals Forum (HCF), the leading international discussion forum for chemicals safety and sound chemicals management.
HCF not only provides a forum to examine the REACH standard within Europe, but also how it fits within the global community of new standards that many countries are implementing to better manage chemical safety and reduce exposure to toxic substances.
HCF 2017 will be held from 8-9 June, 2017 at the Messukeskus Helsinki Convention Centre in Helsinki, Finland. The two-day event addresses opportunities and challenges for chemicals regulation, with panels covering the United Nation’s 2020 goals on chemicals management, sustainable development, chemical assessments, chemical risk and much more. An international collection of speakers from regulatory bodies, industry associations and NGOs will provide insights, with speakers from ECHA, the US EPA, Environment Canada, CEFIC, OECD and many more.
For more information about HCF, visit http://www.helsinkicf.eu.
One of the most exciting fields opening up as a result of efforts to identify new or unforeseen hazards to our waterways and effective methods for treating contaminated wastewater and industrial effluents is the study of nanomaterials and nanotechnology; both as an emerging contaminant in industrial effluents, and a potentially useful tool for water filtration and purification.READ MORE
A significant minority of major depressive disorder patients don’t respond to currently available antidepressant medication. A newly approved treatment, based on the "club drug" ketamine, could change that. In a session at the British Neuroscience Association’s Festival of Neuroscience 2019, the potential mechanisms of ketamine’s antidepressant action were put under examination.READ MORE
Given the complexity of cancer, it’s arguably unlikely that single molecules will work as clinically meaningful biomarkers for cancer. Today, biomarker discovery involves detecting patterns – characteristics or phenotypes that can be measured and monitored throughout a patient’s journey. Here, we look at two approaches being explored in this evolving field.READ MORE